PathoGenesis Tobi

Executive Summary

Twenty-five to thirty percent of potential U.S. Tobi candidates, or 5,000-5,500 cystic fibrosis patients, currently take the drug, PathoGenesis CEO Wilbur Ganz tells analysts. The company hopes to reach 7,000 patients, or 38% of the 18,000 potential U.S. patients, by year-end. Twenty-four sales reps currently promote the cystic fibrosis treatment, approved in December 22, 1997. Ongoing Phase II trials are evaluating Tobi in bronchiectasis and tuberculosis, with an Phase I/II trial in long-term ventilator patients expected to commence in early 1999. Company expects to file IND for its second aerosolized antibiotic, PA-1420 (polymyxin E1) in 1999